Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 42 clinical trials
A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

The study is being conducted to evaluate the tolerability, safety and efficacy of maintenance Fluzoparib monotherapy in patients with gBRCA/PALB2 mutated metastatic pancreatic cancer whose

measurable disease
fluzoparib
pancreatic adenocarcinoma
palb2
blood test
  • 1 views
  • 01 Feb, 2021
  • 23 locations
Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer (CHANGEABLE)

designed to treat metastatic breast cancer patients with DDR gene (BRCA1/2, PALB2, CHEK2, ATM, ATR, BAP1, BARD1, BLM, BRIP1, CHEK1, CDK12, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCM, MRE11A

  • 0 views
  • 09 Jul, 2022
  • 1 location
Talazoparib in Advanced Breast Cancer Patients With Homologous Recombinant Deficiency

Talazoparib has shown clinical efficacy in breast cancer patients with germline BRCA1 or BRCA2 mutations. Beyond BRCA1 and BRCA2 mutations, it is plausible that talazoparib may have activity in patients with homologous recombination defects (HRD).

  • 0 views
  • 07 Oct, 2022
  • 1 location
A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies (CERTIS1) (CERTIS1)

This study will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AZD9574 individually and in combination with anti-cancer agents in patients with advanced cancer that has recurred/progressed.

  • 0 views
  • 28 Oct, 2022
  • 2 locations
Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is shown in part A.

bone disease
soft tissue disease
docetaxel
direct bilirubin
flutamide
  • 0 views
  • 24 Jan, 2021
  • 1 location
COsegregation of VARiants in Panel of Genes (COVAR)

The aim of the COVAR project is to classify reliably a maximum of VUS of the French database in order to use them for the genetic counseling. The results obtained through this study will have a major impact on clinical management of the patients and their families conducting in some …

BRCA1/2
KIT
cancer
breast cancer
cancer of the ovary
  • 17 views
  • 07 Oct, 2022
  • 57 locations
Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

This randomized clinical trial studies how well online genetics educational video with or without pre- and/or post-telephone genetics counseling works in assessing cancer-risk distress in patients with triple negative breast cancer. Online genetic education and telephone genetic counseling may help the doctors learn the stress a person feels about their …

progesterone
genetic counseling
human epidermal growth factor
estrogen receptor
breast cancer
  • 24 views
  • 01 Jul, 2022
  • 2 locations
Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

This is an open-label, multi-center, phase 1b study designed to determine a tolerable dose of CX-5461 administered by IV infusion on Day 1 and Day 8 of a 28-day cycle in patients with selected solid tumours and associated mutations for future Phase II trials. The safety and tolerability of CX-5461, …

  • 2 views
  • 03 Jun, 2022
  • 6 locations
A Single-Arm Phase-II Study of Niraparib in Locally Advanced or Metastatic Solid Tumor Patients With PALB2 Mutations

PALB2 (tPALB2) mutation.

palb2
solid tumor
formalin-fixed paraffin-embedded
corticosteroid
  • 1 views
  • 11 Oct, 2022
  • 68 locations
Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer

This phase II trial studies how well niraparib and dostarlimab work in treating patients with germline or somatic BRCA1/2 and PALB2 mutated pancreatic cancer that has spread to other places in

  • 0 views
  • 16 Oct, 2022
  • 3 locations